CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

17-Apr-2024 - CureVac N.V. and The University of Texas MD Anderson Cancer Center announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, ...

Collaboration to develop vaccine against Helicobacter pylori

Core Facility Animal Models and start-up company Iguana cooperate

17-Oct-2023 - The Core Facility Animal Models (CAM) announces a new collaboration with drug discovery start-up Iguana Biotechnology GmbH (Iguana) to test their innovative vaccine candidate against Helicobacter pylori. Helicobacter pylori is one of the most common infectious diseases worldwide. It is a ...

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

09-Jan-2023 - CureVac N.V. announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK. The preliminary results generated by this ...

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate

01-Apr-2022 - CureVac N.V. announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s ...

CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

01-Jun-2021 - CureVac N.V. announced that the independent Data Safety Monitoring Board (DSMB) has confirmed that the pivotal Phase 2b/3 study (HERALD) for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases. The DSMB confirmed that ...

Second-Generation COVID-19 Vaccine Candidate Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study

Fast onset of strong neutralizing antibody titers after first vaccination

14-May-2021 - CureVac N.V. announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals. ...

CureVac’s COVID-19 Vaccine Candidate Demonstrates Protection Against South African Variant in Preclinical Challenge Study

Full protection of immunized mice from infection and mortality during variant challenge infection

24-Mar-2021 - CureVac N.V. announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 (also referred to as the “South African” variant) and a strain of the original SARS-CoV-2 B1 ...

CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate

Study conducted in Peru and Panama

30-Sep-2020 - CureVac N.V. announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV. The dose-confirmation study, entitled CV-NCOV-002, is being conducted in Peru and Panama and will enroll a total of 690 healthy participants in two distinct ...

Spin-off project successfully developed a COVID-19 vaccine candidate

Quick, efficient and scalable vaccine manufacturing: virus-like particle developed and produced

17-Sep-2020 - With the current pandemic crisis, the lack of worldwide vaccine manufacturing capacity has become a serious concern. ContiVir, a spin-off project at the Max Planck Institute for Dynamics of Complex Technical Systems Magdeburg, has successfully produced a virus-like particle as a COVID-19 vaccine ...

Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate

Phase 1/2a Clinical Trial to Begin in Second Half of July

15-Jun-2020 - Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is ...